Company Encyclopedia
View More
name
Biofrontera AG
B8F.DE
News
View More

Biofrontera AG signs distribution agreement for Ameluz with Propharma in Croatia

Biofrontera AG has signed a distribution agreement with Propharma d.o.o. for the commercialization of Ameluz® in Croatia. Propharma will seek reimbursement for the product, with sales expected to begin by the end of 2026, pending successful reimbursement discussions. Ameluz® is used to treat mild to moderate actinic keratosis and superficial/nodular basal cell carcinoma in adults.

Reuters·
DE
B8F
0.00%
Reuters·
DE
B8F
0.00%

Biofrontera AG completes sale of U.S. Ameluz® and RhodoLED® assets to Biofrontera Inc.

Biofrontera AG has completed the sale of its U.S. Ameluz® and RhodoLED® assets to Biofrontera Inc., transferring all related assets, liabilities, and rights. In return, Biofrontera AG receives a 10% equity stake in Biofrontera Inc. and an earn-out based on U.S. Ameluz® sales until 2043. The agreement also transfers ongoing litigation responsibilities to Biofrontera Inc., allowing Biofrontera AG to focus on its European operations. The operational transfer is expected to be finalized by Q1 2026, streamlining Biofrontera AG's structure and reducing costs.

pressetext·
DE
B8F
0.00%
US
BFRI
-8.13%
pressetext·
DE
B8F
0.00%
US
BFRI
-8.13%

Correction notice regarding the H1 2025 report and the corresponding press release dated September 30, 2025, 00:18 a.m.

Biofrontera AG issued a correction notice regarding its H1 2025 report and a press release dated September 30, 2025. The correction addresses typing errors in the "Outlook and Forecast" sections of both the German and English versions of the report. The corrected EBITDA forecast for 2025 is now EUR 1.5 to 3.5 million, up from the previously stated EUR 0.5 to 1.5 million. Additionally, cash and cash equivalents as of December 31, 2025, are corrected to EUR 1 to 3 million, from EUR 0.5 to 3 million. The updated report is available on the company's website.

pressetext·
DE
B8F
0.00%
pressetext·
DE
B8F
0.00%

Biofrontera AG: BIOFRONTERA REPORTS RESULTS FOR THE FIRST HALF OF 2025

Biofrontera AG reported its financial results for the first half of 2025, showing a 21.5% increase in total revenue to 8,762 TEUR compared to 7,206 TEUR in the same period of 2024. The growth was driven by strong performance in European markets, particularly Germany, where revenue rose by 24%. Despite a net loss of 3,692 TEUR, the company noted significant improvements in EBITDA and gross profit. The restructuring with Biofrontera Inc. is expected to minimize risks in the U.S. market and strengthen its European presence.

pressetext·
DE
B8F
0.00%
US
BFRI
-8.13%
pressetext·
DE
B8F
0.00%
US
BFRI
-8.13%

Biofrontera AG Reports 21.6% Rise in First-Half 2025 Sales to EUR 8.8 Million; Net Loss Narrows to EUR 3.7 Million

Biofrontera AG reported a 21.6% increase in first-half 2025 sales to EUR 8.76 million, with a narrowed net loss of EUR 3.69 million. Sales in Germany rose 24.5%, while EBITDA improved to EUR 2.07 million. The company signed a strategic restructuring agreement with Biofrontera Inc., transferring U.S. market assets in exchange for shares and royalties. New sales guidance for 2025 is projected between EUR 17.0 million and EUR 20.0 million.

Reuters·
DE
B8F
0.00%
Reuters·
DE
B8F
0.00%